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Intracranial electroencephalography (EEG) is commonly used to study epileptogenesis
and epilepsy in experimental models. Chronic gliosis and neurodegeneration at the injury
site are known to be associated with surgically implanted electrodes in both humans
and experimental models. Currently, however, there are no reports on the impact of
intracerebral electrodes on proteins in the hippocampus and proinflammatory cytokines
in the cerebral cortex and plasma in experimental models. We used an unbiased,
label-free proteomics approach to identify the altered proteins in the hippocampus,
and multiplex assay for cytokines in the cerebral cortex and plasma of C57BL/6J mice
following bilateral surgical implantation of electrodes into the cerebral hemispheres.
Seven days following surgery, a repeated low dose kainate (KA) regimen was followed to
induce status epilepticus (SE). Surgical implantation of electrodes reduced the amount of
KA necessary to induce SE by 50%, compared with mice without surgery. Tissues were
harvested 7 days post-SE (i.e., 14 days post-surgery) and compared with vehicle-treated
mice. Proteomic profiling showed more proteins (103, 6.8% of all proteins identified)
with significantly changed expression (p < 0.01) driven by surgery than by KA treatment
itself without surgery (27, 1.8% of all proteins identified). Further, electrode implantation
approximately doubled the number of KA-induced changes in protein expression (55,
3.6% of all identified proteins). Further analysis revealed that intracerebral electrodes
and KA altered the expression of proteins associated with epileptogenesis such as
inflammation (C1q system), neurodegeneration (cystatin-C, galectin-1, cathepsin B,
heat-shock protein 25), blood–brain barrier dysfunction (fibrinogen-α, serum albumin,
α2 macroglobulin), and gliosis (vimentin, GFAP, filamin-A). The multiplex assay revealed a
significant increase in key cytokines such as TNFα, IL-1β, IL-4, IL-5, IL-6, IL-10, IL12p70,
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IFN-γ, and KC/GRO in the cerebral cortex and some in the plasma in the surgery group.
Overall, these findings demonstrate that surgical implantation of depth electrodes alters
some of the molecules that may have a role in epileptogenesis in experimental models.
Keywords: intracerebral electrodes, traumatic brain injury, neuroinflammation, proinflammatory cytokines,
epilepsy, blood-brain barrier, seizure threshold
INTRODUCTION
In some animal models of epilepsy, cranial surgery (drilling
burr holes through the skull) is required to implant electrodes
for acquiring electroencephalography (EEG) recordings (1–4)
and electrical kindling (5, 6) or to implant a cannula for
intracerebral administration of drugs (7–9). The incidence of
post-craniotomy seizures in humans has been estimated to be
15–20% (10). To our knowledge, no post-operative spontaneous
seizures have been reported in rodent models. A study in the
rat model, however, revealed abnormal EEG patterns (11), and
several other studies in rodent models reported a reduced seizure
threshold to chemoconvulsants following cranial surgery (12–
15). Implantation of electrodes for kindling causes focal neuronal
damage, resembling a penetrating brain injury in humans (12,
13, 16, 17), and it is unclear the extent to which the injury
itself contributes to the kindling process (14). Recently, we
demonstrated that even epidurally placed electrodes reduce
seizure threshold induced by systemic administration of kainate
(KA) (15).
KA is widely used as a chemoconvulsant in experimental
rodent models for the study of the cellular and molecular
mechanisms involved in epileptogenesis (18, 19). Continuous
EEG is employed for the detection of the onset and progression
of chronic epilepsy, via monitoring of the frequency, duration,
and semiology of spontaneous recurrent seizures (SRS) and
tracking of other epilepsy-associated electrographic signatures
such as interictal spikes (2, 3, 20–26). Acquisition of EEG from
experimental models requires the implantation of electrodes on
either the dura mater or into the brain. It is presumed that
the mechanism of epileptogenesis following chemoconvulsant-
induced status epilepticus (SE) in experimental animals is
independent of electrode implantation, but the mechanisms are
not completely known. Understanding the differential expression
of proteins due to surgical implantation of electrodes alone
and subsequent exposure to chemoconvulsant may provide
some insight into the mechanism of epileptogenesis. Three
proteomics studies have been reported from rodent epilepsy
models so far: a C57BL/6J mouse model with intrahippocampal
KA approach but without electrodes (27), a rat pilocarpine model
without electrodes (28), and an amygdala electrical kindling in
female rats (29). There are currently no reports, however, on
demonstrating the impact of surgically implanted intracerebral
electrodes on protein expression in the hippocampus or cerebral
cortical and plasma cytokines levels. Surgical procedure reduce
seizure threshold, thereby requiring less KA to induce severe
SE (15). This is likely due to associated inflammation in
the brain; however, the mechanistic pathways are still largely
unknown. To address this, we conducted a proteomics study on
the hippocampus and proinflammatory cytokine assay of both
cortical tissue and plasma in C57BL/6J mice with and without
the implantation of intracerebral electrodes and with and without
KA exposure. Proteins that alter due to surgical procedures
and KA may facilitate the development of epilepsy and may




All experimental procedures in animals were reviewed and
approved by the University of Liverpool Ethics Committee as
per the Animal (Scientific Procedures) Act, 1986 (UK). All
experiments were conducted at the University of Liverpool. Adult
male C57BL/6J mice (25–30 g; 8–9 weeks old) were purchased
from Charles River, Margate, UK, and habituated for at least 4
days prior to the procedures. All animals had unlimited access
to food and water. To determine the effects of intracerebral
electrodes on seizure threshold for KA-induced SE, we used 15
mice that had undergone surgery and compared with a large
cohort of mice (n = 187) without surgery. For the proteomics
and Meso Scale Discovery (MSD) multiplex studies, we used a
total of eight KA-treated mice (four mice per group; surgery and
without surgery). These eight mice were chosen based on similar
SE severity i.e., >45min of convulsive seizures during the 2 h SE
period from the first stage 5 seizure to diazepam treatment, and
the KA dose of 20–25 mg/kg (4/5 doses of 5 mg/kg). All other
mice were euthanized at various time points post-SE, and the
tissues were archived for the other studies (not reported here). An
additional eight mice (four per group) of the same age from each
vehicle-treated (with and without surgery) served as controls
for surgery and KA groups. All animals were euthanized at the
end of the experiment with pentobarbitone (60 mg/kg, i.p.). The
experimental design and experimental groups are illustrated in
Figure 1. The experiments were designed and reported as per the
principles of the ARRIVE guidelines (30).
Surgical Procedure for Intracerebral
Electrode Implantation
Eight mice were anesthetized with 3% isoflurane in 2 L/min
oxygen until the loss of pinch reflex and maintained at
2% isoflurane during the surgery. The head was shaved
and disinfected with Videne. Before surgery, animals were
administered with a prophylactic antibiotic, Baytril R© (Bayer
Health group, Germany, 5 mg/kg, s.c.), and an analgesic,
buprenorphine (Vetergesic R©, Reckitt Benckiser Healthcare, UK,
0.3 mg/kg, i.m.). An incision was made through the skin, muscle,
and connective tissue over the skull, as described previously (31).
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FIGURE 1 | The experimental design. The brain image on the left illustrates the gross impact of the intracerebral electrodes (surgery), and the image on the right is
from a mouse with no surgery.
Bilateral burr holes of 1.8mm diameter were made through the
skull corresponding to the cerebral hemispheres and underlying
hippocampi (5mm cranial to lambda and 2mm lateral to midline
over each hemisphere). We used sterile DSI electrode wires (Data
Scientific International, USA). The electrodes used were twisted
(coiled bifilar) and bipolar, i.e., they measure the voltage between
the two leads between the electrode coil in the (+) red insulated
lead and the electrode coil in the negative (−) clear insulated lead.
Each of the two electrode leads consists of a high-performance
nickel cobalt alloy as used in medical implants. The electrode
is a coil consisting of two wires (bifilar), but the two wires are
electrically common to one another. The diameter of the coil
was 0.356mm. The coil insulation was a medical grade silicone
with an outer diameter of 0.94mm. Following removal of the
electrodes’ insulation, a V-shaped bend was made in the wire
with an extended flat terminal end (∼2mm). The length/depth
of the V-shaped electrode was 2.8mm, which was enough to
penetrate the cortex. The width of the V bend varied from bottom
to the top (0.5–2mm), which was sufficient to pass through
the 1.8mm burr hole. The V-shaped electrode was manually
inserted through the burr hole. The flat free terminal end and
an insulated wire at the other end of the hole were touching the
skull. Electrodes were secured to the skull with dental cement
constituted from Alphacryl Rapid Repair and methyl acrylate
(National Dental Supplies, Southport, U.K). The incision was
sutured using Polysorb 4.0 and reinforced with VetbondTM Tissue
adhesive (3M Animal Care Products, USA). All animals were
given subcutaneous injections of saline for rehydration and soft
food to facilitate recovery of their body weight, post-surgery.
Repeated Low Doses of KA Administration
to Induce SE
KA (Abcam Biochemicals R©, Cambridge, UK) was dissolved in
sterile distilled water (DW) and administered at 5 mg/kg per
dose or an equal volume of DW as the vehicle. Sixteen mice
were divided into four groups of four mice each, which were
either surgically implanted with intracerebral electrodes or not,
and either treated with KA or vehicle (DW), i.p., in a two-
by-two trial design [the four groups are vehicle (no surgery),
vehicle (surgery), KA (no surgery), and KA (surgery)]. KA-
treated animals were scored for seizure severity using a modified
Racine scale (32). The stages include stage 1, freezing; stage
2, head nodding; stage 3, rearing; stage 4, rearing and falling;
and stage 5, generalized seizures. Repeated doses of KA were
given at 30min intervals until animals reach stage 5 seizures,
after which the dosing was discontinued as described previously
(32). Each cohort included 8–10 mice since using more animals
in a cohort would be difficult to manually quantify initial SE
severity, although two experimenters scored SE at the same time.
KA-surgery and KA no surgery groups were treated with KA
simultaneously. Vehicle-treated animals were matched to KA-
treated mice by number of injections. Two hours after the onset
of stage 5 seizures, all mice that received KA and their vehicle
counterparts were given diazepam (10 mg/kg, i.m., Hameln
Pharmaceuticals Ltd, Gloucester, UK) to standardize the duration
of behavioral seizures in KA treated animals. The objective of
the study was to determine the impact of surgically implanted
intracerebral electrodes in the brain on protein and cytokine
expression; therefore, EEG was not acquired (dummy telemetry
devices were used) during the 7 day post-SE period. Videos,
however, were acquired to confirm that the KA-treated mice had
SRS during the following 7 days.
Tissue Collection, Sample Preparation, and
Protein Estimation
Seven days following the induction of SE with KA, all mice,
including the vehicle-treated, were euthanized. Blood samples
were collected by cardiac puncture into lithium heparin-coated
tubes, centrifuged at 2,000× g for 20min at 4◦C for the isolation
of plasma, and stored at −80◦C. Brains were removed, and
the whole hippocampi and cerebral cortices including the tissue
surrounding the electrodes were dissected, collected in cryovials,
and snap-frozen in liquid nitrogen. Brain and plasma samples
were stored at−80◦C until required.
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Hippocampi and cortical tissue samples were thawed on ice,
dabbed with a sterile tissue paper to remove the water, and
weighed before performing assays. Tris lysis buffer containing
1:50 protease inhibitor was added to each sample at a volume
of 10 µl/mg of tissue. Samples were then homogenized using
a TissueRuptor, sonicated, and centrifuged at 10,000 × g for
20min at 4◦C. The resulting supernatants were aliquoted, and
protein concentrations were determined using a Bradford assay
(Sigma Aldrich, UK). Bovine serum albumin (BSA) standards
were prepared using a stock solution containing 4 g/ml BSA.
BSA standards were diluted with distilled water to concentrations
ranging from 100 to 1,400µg/ml. A volume of 10 µl of each
sample and BSA standards were added in duplicates to a 96-
well plate. Bradford reagent (200 µl) was added to each well,
and the 96-well plate was incubated at room temperature for
5min. The maximum absorbance frequency for each sample was
measured at 595 nm using a multimode plate reader (DTX 880;
Beckman Coulter, USA), and the protein content of samples was
determined by comparing to a standard curve generated using a
serial dilution of BSA. Tissue supernatants were diluted to 1:50
with distilled water before protein assay. Plasma samples were
thawed on ice, vortexed, and centrifuged at 13,000× g for 10min
at 4◦C. Hippocampi lysates were used for proteome analysis, and
cortical lysates and plasma were used for MSD V-PLEX assay.
Hippocampi Lysate Processing for
Proteomics
The hippocampal lysates were processed for proteome analysis,
as described previously (33). For digestion, 15 µl (∼100 µg) of
homogenate was diluted to 160 µl of ammonium bicarbonate
in LoBind tubes. The proteins were denatured using 10 µl of
1% (w/v) RapiGestTM SF surfactant (Waters, Manchester, UK) in
25mM ammonium bicarbonate followed by incubation at 80◦C
for 10min. Samples were reduced by adding 10 µl of 60mM
dithiothreitol and incubated at 60◦C for 10min and alkylated
by adding 10 µl of 180mM iodoacetamide and incubated at
room temperature in the dark for 30min. Trypsin (Sigma, UK)
was reconstituted in 50mM acetic acid to a concentration of
0.2 µg/µl. Digestion was performed by the addition of 10
µl of trypsin to the samples followed by incubation at 37◦C
overnight. Trifluoroacetic acid (TFA) was added to each sample
for acidification, and the samples were incubated at 37◦C for
45min. Samples were centrifuged at 17,000 × g for 45min,
and the supernatant was transferred to a LoBind tube. The
centrifugation step was repeated, and 10 µl of supernatant was
transferred to a total recovery vial for LC-MS analysis. Pre- and
post-acidification digest was analyzed by SDS-PAGE to confirm
complete digestion.
LC Separation
All peptide separations were carried out using a nanoAcquity
UPLCTM system (Waters MS Technologies, Manchester, UK), as
previously described (33). For each analysis, 1µl of sample digest
was loaded onto a trapping column (C18, 180µm × 20mm,
Waters), using partial loop injections for 3min at 5 µl/min with
an aqueous solution containing 0.1% (v/v) TFA and 2% (v/v)
acetonitrile. The sample was resolved on an analytical column
(nanoAcquity UPLCTM HSS T3 column, C18 150mm × 75µm
inner diameter, 1.8µm, Waters) using a mobile gradient phase
composed of a cocktail of aqueous (A) and organic (B) solvents.
Solvent A contained 0.1% (v/v) formic acid in HPLC grade water,
and solvent B contained 0.1% (v/v) formic acid in HPLC grade
acetonitrile. Separations were performed by applying a linear
gradient of 3 to 40% solvent B over 90min at 300 nl/min followed
by a washing step (5min at 99% solvent B) and an equilibration
step (15min at 3.8% solvent B). An equivalent to 500 ng of
protein for each sample was injected.
Mass Spectrometry
The LTQ-Orbitrap Velos instrument (Thermo Fisher) was
operated in the data-dependent mode to switch between full-scan
MS and MS/MS acquisition automatically. Survey full-scan MS
spectra (m/z 3,350–2,000) were acquired in the Orbitrap with
30,000 resolution (m/z 400) after the accumulation of ions to 1
× 106 target value based on predictive automatic gain control
values from the previous full scan. The 20 most intense multiply
charged ions (z ≥ 2) were sequentially isolated and fragmented
in the linear ion trap by collision-induced dissociation with a
fixed injection time of 100ms. Dynamic exclusion was set to
20 s. Typical mass spectrometric conditions were as follows: spray
voltage, 1.5 kV, no sheath and Auxillary gas flow; heated capillary
temperature, 200◦C; normalized CID collision energy 35%. The
MS/MS ion selection threshold was set to 500 counts, and a 1.2 Da
isolation width was set. A metal-coated picotip (New Objective,
Presearch, UK) was used in the nanospray assembly and was
maintained at a voltage of 1,500 V.
Proteome Identification and Analysis
The hippocampi from all four groups in this study were processed
simultaneously for proteomics using the same protocol and the
instrument that was used in our previous study (33). We used
the vehicle and KA (with no surgery) group’s raw data from our
recently published study (33) to compare with surgery groups.
All four raw data sets were reanalyzed with Proteome Discoverer
2.2.0.388. The data were searched using Mascot 2.2.07 against
Uniprot-Mus musculus with quantification using the Minora
feature detector. Peptide validation was performed using the
Percolator node within Proteome Discoverer. The searches were
performed with static modifications of carbamidomethyl (Cys),
dynamic modifications of oxidation (Met), and deamidation
(Asn, Gun).
Further analysis was performed using the R package
MethaboanalystR 2.0 (34), which contains R functions and
libraries in the MetaboAnalyst webserver (35). Upon checking
the data integrity as satisfactory (i.e., no peptide with more
than 50% missing replicates, and positive values for the area),
missing value estimation was imputed using the Singular Value
Decomposition (SVD) method. Non-informative values that
were near-constant throughout the experimental conditions
were detected using the interquartile range (IQR) estimation
method and deleted. Data were normalized using the Quantile
normalization method. Data transformation was performed
based on Generalized Logarithm Transformation (glog) to make
individual features more comparable. The group samples were
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compared by t-test for paired groups with the adjusted p-
value and False Discovery Rate (FDR) set at 0.01. Fold change
analysis with a threshold of 2 was performed to compare the
absolute value of change between group values (for paired
groups). A volcano plot was created to combine the fold change
and the two-sample t-test analysis. The PCA analysis was
performed using the prompt package, and pairwise score plots
were created to provide an overview of the various separation
patterns among the most significant components. Partial least
squared (PLS) regression was then performed using the plsr
function provided by the R pls package to predict the continuous
and discrete variables. A PLS-DA model was built to classify
and cross-validated PLS using the caret package. The uniport
protein ids that were altered with the p < 0.01 were used to
retrieve the corresponding KEGG ids using the “Retrieve/ID
mapping” tool of UniProt (accessible at http://www.uniprot.org/
uploadlists/). KEGG ids were then used to retrieve the biological
pathway association of the proteins. Enrichment analysis was
performed using the Database for Annotation, Visualization,
and Integrated Discovery (DAVID) 6.8 Tools (36, 37). The
one-way analysis of variance (ANOVA) was used to determine
whether there were any significant differences between the means
±SEM within four groups. Post-hoc analysis was performed with
Fisher’s Least Significant Difference method. Proteins with FDR
values <0.01 were considered significant. Box plots were created
for all significantly altered proteins determined by ANOVA
(Supplementary Figure 1).
Meso Scale Discovery Assay
Reagents Preparation
The standards, antibody detection solution, and read buffer were
prepared in accordance with the manufacturer’s instructions
(MSD Kit # K15048D-1). All reagents were warmed to room
temperature before preparation. The multi-analyte lyophilized
calibrator, supplied by MSD, contains the highest concentration
of all the cytokines and served as the standard stock for the
assay. The calibrator was reconstituted in 1,000 µl of Diluent 41
(MSD, USA), mixed by vortexing, and left for 5min before serial
dilution. A series of standards were prepared by serial dilution of
the calibrator solution by adding 100 µl of the calibrator to 300
µl of Diluent 41 and vortex-mixed, and the process was repeated
five times to generate a total of seven standards. Diluent 41 alone
was used as the blank. The kit provided 10 separate detection
antibodies, 60 µl of each at 50X stock solution. All detection
antibody solutions were combined together (600 µl) and added
to 2,400 µl of Diluent 45 (MSD, USA) to achieve 1:50 dilution.
Reader buffer T 4X stock solution (MSD, USA) was diluted to 1:2
with distilled water.
Linearity of Dilution for the MSD V-PLEX Kit
The linearity of dilution was first performed on 16 wells of the
customized 96-well plate using two cerebral cortices supernatant
samples. One sample was from the vehicle (no surgery) group,
while the other sample was from KA-treated (surgery). These
samples were predicted to have the least and the highest amount
of inflammatory changes, respectively, due to the extent of
insult to the brain. The cortical supernatants or plasma samples
were serially diluted to 1:2, 1:4, 1:8, and 1:16 using Diluent
41 (MSD). The observed values were assessed relative to the
standard curve for all 10 inflammatory cytokines. The results
were calculated based on the standard curve, and the observed
concentration was multiplied by the dilution factor. The criteria
for acceptable dilutional linearity were for the corrected observed
concentrations to vary no more than 80% to 120% of the
theoretical concentration between each serial dilution for each
analyte (38).
MSD V-PLEX Assay Protocol
The assay was performed in accordance with the manufacturer’s
instructions (MSD kit reference K15048D-1). Plasma samples
were diluted 1:2 using Diluent 41. The standards, blank, and
samples (cortical lysates or plasma) solution were measured in
duplicates, with 50 µl of each solution added to an allocated
well within the customized 96-well plate. The plate was sealed
and incubated at room temperature on a shaker for 2 h. After
incubation, the plate was washed three times with wash buffer,
and 25 µl of the diluted detection antibody was added to each
well, the plate resealed, and incubated at room temperature on
a shaker for a further 2 h. After antibody incubation, the plate
was washed three times, as previously described, and then 150
µl of 2X read buffer T was added to each well. The plate was
then placed on the MSD instrument and read immediately.
The reading of the V-Plex plate was performed using the MSD
SECTOR Imager 2400, according to the manufacturer’s manual
(MSD, USA). The plate had an MSD barcode that allowed the
SECTOR Imager to detect the type of plate being run. The
data generated was automatically analyzed with a template using
the Discovery Workbench version 4.0 software. The cytokines
levels were expressed in pg/ml for plasma and pg/mg of protein
detected in a 100 mg/ml tissue lysate, determined using the
Bradford protein assay. One-way ANOVA with Tukey’s post hoc
analysis was performed using the SPSS software.
RESULTS
Intracerebral Electrodes Reduced Seizure
Threshold for KA-Induced SE at Day 7
Post-surgery
The rationale for choosing the 7 day time point post-SE, in
contrast to the early or later time points, was based on our
previous work that demonstrated a significant increase in gliosis,
neurodegeneration, and neurogenesis in C57BL/6J mouse KA
model at 7 day post-SE (26). KA-induced seizure susceptibility
of mice with surgically implanted intracerebral electrodes was
compared with no surgery (naïve) animals. We assessed the
total amount of KA required to induce stage 5 seizures in both
surgery and non-surgery groups at day 7 post-surgery. Electrodes
implanted mice required significantly less KA (15.78 ± 1.47
mg/kg; n = 15) than non-implanted mice (27.98 ± 0.6 mg/kg;
n = 187) to induce generalized convulsive seizures (p < 0.01;
Figures 2A,B). We had to use a large cohort of naïve mice to
cover a wide range of KA doses to achieve stage 5 seizures. There
was a left shift in the KA dose-response curve in the surgery group
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FIGURE 2 | Impact of surgery on seizure threshold in response to kainate (KA). (A,B) The mean (A) and the total (B) KA dose required to induce generalized
convulsive seizures (stage 5 on the Racine scale) in C57BL/6J mice that were either implanted with intracerebral electrodes (Surgery, n = 15) or not implanted (no
surgery, n = 187). KA was administered 7 days post-surgery. In graph A, the data are expressed as the mean (±SEM) KA dose (mg/kg) and compared the groups
using a two-sample t-test (**p < 0.01). The data in B are expressed as a percentage of the total number of animals in each group that reached stage 5 seizures at
each dose increment. (C) The dose-response data for KA are expressed as a cumulative percentage of the total number of animals in each group.
when compared with the group without surgery (Figure 2C).
The range of total KA doses for post-surgery mice was 5–30
mg/kg, and for mice without surgery, the range was 15–55 mg/kg
(Figure 2B). After a single dose of 5 mg/kg KA, 18.75% of mice
in the post-surgery group experienced generalized seizures (stage
5), whereas no mice that had not previously undergone surgical
implantation of electrodes had convulsive seizures (Figure 2C).
At a total dose of 30 mg/kg KA, all mice that had undergone
surgery experienced generalized seizures, compared with 74.4%
of naïve mice (Figure 2C). Of these, four animals from each
group that had similar SE severity (continuous generalized
seizures lasting for >45min) and KA doses (four to five doses
of 5 mg/kg) were used for proteomics and cytokine assays. The
remaining animals were euthanized at various time-points post-
SE and used for other analyses, and not reported here. Video
analysis of all eight KA-treatedmice used in this proteomics study
had a minimum of one SRS during the 7 days post-SE.
After the mice were euthanized, the extent of gross damage
(similar in all animals) was confirmed, while the hippocampus
was separated from the cerebral cortex under a dissection
microscope. Also, clear electrode marks on the cerebral cortices
were visible in all animals (an example is shown in Figure 1). The
hippocampi were used for proteomics and the cortical tissue and
serum for cytokine assays.
Overall Changes in Proteins in the
Hippocampus in Response to Surgery and
KA at 14 Days Post-surgery (i.e., 7 Days
Post-SE)
The number of proteins identified from the raw data in which
expression was significantly altered (p < 0.01) between vehicle
and KA-treated mice with or without surgery, as searched for
against the UniProt mouse database, is listed in Table 1. Data
presented as the absolute number of proteins with significant
changes (downregulated, upregulated, and total significant) as
a percentage of the total number of proteins identified in the
study (Table 1). The surgery increased higher number of proteins
regardless of whether they were subsequently treated with KA
or vehicle (A, B in Table 1). The impact of surgery alone on
the percentage of protein expression was greater than that of
KA-induced seizures in mice that had no surgery (103 vs. 27
total significant; 6.8 vs. 1.8%). KA had a greater effect in the
surgery group (C, 55 proteins altered; 3.8% of total significant)
than in no surgery group (D, 27 proteins altered; 1.8% of
total significant) (Table 1). We also investigated whether any
of the endogenous resolving proteins were altered in response
to surgery and/or KA induced brain trauma. We detected
leukotriene A-4 hydrolase (FDR, 0.92; p= 0.89, but interestingly,
not the leukotriene B4, a chemoattractant at an early phase of
insult) and prostaglandin E synthase (FDR, 0.46, p = 0.26), but
there were no significant differences. Also, our search did not
yield any lipoxins or resolvins.
Differential Expression of Proteins in the
Hippocampus in Response to Surgery Alone or KA
(With or Without Surgery) at 14 Days Post-surgery
(i.e., 7 Days Post-KA)
One-way ANOVA with Fisher’s post-hoc analysis of all four
groups revealed a significant increase in the proteins that
have role in neuroinflammation including gliosis [C1q
system, glial fibrillary acidic protein (GFAP), and vimentin]
and neurodegeneration (cystatin-C and galectin-1) in both
surgery groups treated with KA or vehicle, and in KA-treated
group without surgery. The Ras and Rab related proteins
(Rab6a and Rras2) and calcium/calmodulin-dependent protein
kinase IIa (CaMKIIα that have a role in neuronal plasticity
were significantly reduced in all three groups (Table 2,
Supplementary Figure 1). In KA groups, with or without
surgery, glypican-1, heat shock protein beta-1 (HSP25),
unconventional myosin-Va, neurosecretory protein VGF (VGF-
derived peptide TLQP-62), and EF-hand domain-containing
protein D2 (Swiprosin-1) were significantly upregulated,
while the voltage dependent GABA A transporter (GAT-1)
and glutamine synthase (GS) were downregulated (Table 2,
Supplementary Figure 1). In addition to the above listed
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TABLE 1 | Comparison of the changes in the expression of proteins in the hippocampus between treatment groups are reported as absolute numbers and percentage of
total identified proteins.
Treatment groups Downregulated Upregulated Total significant % significant of all
proteins identified
(A) Vehicle: Surgery vs. no surgery 59 44 103 6.80%
(B) KA: Surgery vs. no surgery 47 35 82 5.40%
(C) Surgery: KA vs. vehicle 32 23 55 3.60%
(D) No surgery: KA vs. vehicle 16 11 27 1.80%
Treatment groups (n = 4) comprised animals that had undergone surgery for the implantation of intracerebral electrodes or no surgery and that subsequently received KA to
induce seizures or vehicle as a control. Data reports proteins with significantly altered between groups (t-test, p < 0.01), either as absolute numbers or as percent significant of all
identified proteins.
proteins, the proteins that were up- or downregulated in surgery
groups (with or without KA) are listed in Table 2 and box plots
for each protein are illustrated in Supplementary Figure 1.
Differential Expression of Proteins in the
Hippocampus in Response to Surgically Implanted
Intracerebral Electrodes (Without KA)
A large number of proteins were altered in mice with
intracerebral electrodes compared with the mice without
surgery and electrodes (103 proteins, p < 0.01; Tables 1, 3,
Supplementary Table 2). An overview of the variation of
all proteins between surgery and without surgery groups is
illustrated in volcano plot, PCA, and heatmap (Figures 3A,B,
4A). The proteins associated with the innate immune system
such as complement components C1q a, b, and c were increased
by 3.34-fold (p = 0.0003) in the surgery group. Astroglia
cytoskeletal proteins such as vimentin and GFAP were also
upregulated in the surgery group (>2-fold, p < 0.0001). The
other key proteins that were upregulated by >2-fold (p <
0.001) were F-box and leucine-rich repeat protein 8 (FBXL8),
solute carrier family 12 member 2 (basolateral Na-K-Cl
symporter), and dehydrogenase/reductase SDR family member
1 (DHRS1). The KEGG pathway enrichment analysis revealed
a significant increase in proteins involved in the process of
neurodegeneration, neuroinflammation, and oxidative stress
(for example, prion disease pathway proteins—C1qs and Stip1;
Chagas disease pathway proteins—serine/threonine-protein
phosphatase 2A (PP2A) related proteins; glutathione pathway
proteins such as glutathione S-transferase and peroxiredoxin-6)
(Supplementary Table 4, Supplementary Figure 2). FDR for
the proteins in prion disease and ribosome pathways were ≤1,
while the other pathways were >9 (Supplementary Table 4).
Differential Expression of Proteins in the
Hippocampus in Response to KA in Surgically
Implanted Intracerebral Electrodes vs. KA Without
Surgery at 14 Days Post-surgery (i.e., 7 Days
Post-SE)
We analyzed the impact of KA-induced SE on protein levels in
mice that had surgery and without surgery. The volcano plot,
PCA, and heatmap represent an overview of the variation in
protein expression between the treatment groups (Figures 3C–E,
4B). The proteins that were significantly increased by >2-
fold (p < 0.01) in response to KA in surgery group when
compared with no surgery group were BBB function-related
proteins such as fibrinogen-α (aids as an adhesive substrate
for platelets, endothelial cells, and leukocytes), pregnancy zone
protein (α2 macroglobulin), serum albumin, serotransferrin
(transferrin/β1 metal-binding globulin), and α1-antitrypsin
1–4 (α1 protease inhibitor 4, a serum glycoprotein) (Table 4).
FBXL8 and C1qb were also increased. A cation-coupled
chloride transporter (Na-K-Cl symporter/SCL12A), a core cycle
regulator (sister chromatid cohesion protein PDS5 homolog
A), and a cytoskeletal protein Filamin-A (FLN-A/actin-binding
protein 280) were significantly increased in KA-treated mice
in the surgery group (Table 4, Supplementary Table 3). The
list of KEGG pathways and the proteins altered are listed in
Supplementary Table 5. The most striking KEGG pathway
proteins affected in the surgery group in response to KA,
with <1% FDR, were the synaptic vesicle cycle pathway
proteins. If we consider p ≤ 0.05, however, specific proteins
involved in the regulation of actin cytoskeleton, prion diseases
(neurodegeneration and neuroinflammation), endocytosis,
phosphatidylinositol, and neurotrophin signaling pathways,
Legionellosis (inflammation-related), glioma, and long-term
potentiation were significantly affected in pathway enrichment
analysis (Supplementary Table 5, Supplementary Figure 3).
Multiplex Assay to Determine Differential
Expression of Cytokines in Cortical Tissue
and Plasma
We used the MSD multiplex kit since it had
cytokines/chemokines relevant to epilepsy/seizures and trauma
(references are included in the summary Table 6). The other
advantages of this kit over the other commercial multiplex kits
are as follows: (i) it requires small volume of analyte (25 µl,
in contrast to 50 µl), therefore suitable for mouse tissue; (ii)
it is compatible for both plasma and brain lysate; and (iii) it
measures both high and low abundance analytes with a 5-Log+
dynamic range.
Linearity of Dilution Assessment and Detection
Ranges of Cytokines in 1:2 Diluted Test Samples
A serial dilution of mouse cortex supernatant was conducted to
determine the optimum dilution required for the MSD assay for
each cytokine. Two cortical supernatants were used: one from
without surgery and KA (no surgery+ vehicle) that was expected
Frontiers in Neurology | www.frontiersin.org 7 July 2021 | Volume 12 | Article 625017
Tse et al. Electrodes-KA Effects on Brain Proteins







FDR Abundance on a log scale
Veh-NoSurg Veh-Surg KA-NoSurg KA-Surgery
Proteins upregulated in surgery vehicle and both KA groups
P03995 Glial fibrillary acidic protein
(GFAP)
Gfap 31.792 5.43E-06 5.265 0.00138 25.55244 27.025413 26.87475 27.968345
P20152 Vimentin Vim 20.7 4.91E-05 4.3091 0.00361 23.70164 25.16986 24.87103 26.487395
P98086 Complement C1qa C1qa 15.099 0.000224 3.6494 0.00901 17.52368 19.70244 18.78533 19.755233
P14106 Complement C1qb su C1qb 25.31 1.78E-05 4.7495 0.00191 19.04926 20.753115 19.97015 21.130523
Q02105 Complement C1q subunit C C1qc
C1qg
16.908 0.000131 3.8812 0.00633 18.60421 20.583218 19.43826 20.605043
P16045 Galectin-1 (Gal-1/Galaptin) Lgals1
Gbp
23.294 2.72E-05 4.566 0.00244 18.55418 19.299368 19.29811 20.263458
P21460 Cystatin-C (Cystatin-3) Cst3 15.395 0.000205 3.6888 0.00869 21.29772 21.565828 21.74042 22.158848
P62301 40S ribosomal protein S13 Rps13 20.655 4.96E-05 4.3044 0.00361 21.70742 21.852868 21.85315 21.976885
Proteins downregulated in surgery vehicle and both KA groups
P35279 Ras-related protein Rab-6A
(Rab-6)
Rab6a 18.567 8.37E-05 4.077 0.00553 21.63157 21.371815 21.51557 21.370305
P62071 Ras-related protein R-Ras2 Rras2 17.853 0.000101 3.9946 0.00576 20.50515 20.053165 20.35101 19.987185
P11798 Calcium/calmodulin-
dependent protein kinase IIa
(CaMK-IIa)
Camk2a 24.743 0.00002 4.6992 0.00191 28.23778 28.094555 28.03671 27.681833
Proteins upregulated in both KA groups (with or without surgery)
Q9QZF2 Glypican-1 [Cleaved into:
Secreted glypican-1]
Gpc1 33.445 4.15E-06 5.3816 0.00138 19.79506 19.762235 20.0398 20.213773




26.34 1.45E-05 4.8385 0.00191 18.34595 18.024863 20.10053 21.608808
Q99104 Unconventional myosin-Va Myo5a
Dilute
17.692 0.000106 3.9756 0.00576 23.74006 23.75106 23.87258 23.905998
Q0VGU4 Neurosecretory protein VGF
(VGF-derived peptide
TLQP-62)





17.443 0.000113 3.946 0.00576 23.16364 23.261423 23.45649 23.668985







17.805 0.000103 3.9889 0.00576 23.44462 23.413773 23.06983 22.927308
P15105 Glutamine synthetase (GS) Glul Glns 14.75 0.00025 3.6022 0.00969 26.8151 26.797415 26.51625 26.618135






66.863 9.25E-08 7.0337 0.00014 21.23233 21.911073 21.15768 21.993103
Q9D0M5 Dynein light chain 2,
cytoplasmic (DLC8)
Dynll2 Dlc2 58.2 2.02E-07 6.6954 0.00015 22.21056 21.12811 22.18282 21.00142




36.452 2.62E-06 5.5812 0.00134 19.8724 20.885968 19.80909 20.84635
P03995 Glial fibrillary acidic protein
(GFAP)
Gfap 31.792 5.43E-06 5.265 0.00138 25.55244 27.025413 26.87475 27.968345
Q8CIG9 F-box/LRR-repeat protein 8
(F-box protein FBL8)






29.347 8.27E-06 5.0823 0.0018 21.12106 21.556105 21.02334 21.506653
(Continued)
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FDR Abundance on a log scale
Veh-NoSurg Veh-Surg KA-NoSurg KA-Surgery
Q3URK3 Methylcytosine dioxygenase




27.562 1.15E-05 4.9404 0.00181 19.20219 20.01175 18.97767 19.870405





27.452 1.17E-05 4.9313 0.00181 21.57142 22.651055 21.59296 22.838318
P10605 Cathepsin B/B1) Ctsb 15.512 0.000198 3.7042 0.00868 21.24294 21.535165 21.29265 21.835295




26.34 1.45E-05 4.8385 0.00191 18.34595 18.024863 20.10053 21.608808
Q5SSL4 Active breakpoint cluster
region-related protein
Abr 24.9 1.94E-05 4.7132 0.00191 21.39741 22.032938 21.47865 22.021938
P16045 Galectin-1 (Gal-1/Galaptin) Lgals1
Gbp
23.294 2.72E-05 4.566 0.00244 18.55418 19.299368 19.29811 20.263458
Q9WVA3 Mitotic checkpoint protein
BUB3
Bub3 22.904 2.96E-05 4.5289 0.00251 19.26223 19.585013 19.20765 19.39816
Q02105 Complement C1qc C1qc
C1qg
16.908 0.000131 3.8812 0.00633 18.60421 20.583218 19.43826 20.605043
P20152 Vimentin Vim 20.7 4.91E-05 4.3091 0.00361 23.70164 25.16986 24.87103 26.487395
P62301 40S ribosomal protein S13 Rps13 20.655 4.96E-05 4.3044 0.00361 21.70742 21.852868 21.85315 21.976885
Q9CQJ6 Density-regulated protein
(DRP)
Denr 19.443 6.69E-05 4.1749 0.00464 19.67067 20.136073 19.63894 20.130675




18.078 9.53E-05 4.0209 0.00576 18.75928 19.305835 18.70097 19.563578
P21460 Cystatin-C (Cystatin-3) Cst3 15.395 0.000205 3.6888 0.00869 21.29772 21.565828 21.74042 22.158848
P98086 Complement C1qa C1qa 15.099 0.000224 3.6494 0.00901 17.52368 19.70244 18.78533 19.755233
Proteins downregulated in both surgery groups (vehicle and KA)
P32037 Solute carrier family 2-(Glucose









21.247 4.31E-05 4.3654 0.00347 19.89033 19.44267 19.63764 19.222073
Q8C0E2 Vacuolar protein
sorting-associated protein 26B
Vps26b 27.386 1.19E-05 4.926 0.00181 21.77001 21.464778 21.70237 21.46987




18.428 8.69E-05 4.0612 0.00553 21.26101 20.738385 21.16048 20.689868




18.567 8.37E-05 4.077 0.00553 21.63157 21.371815 21.51557 21.370305











17.443 0.000113 3.946 0.00576 23.16364 23.261423 23.45649 23.668985
P39053 Dynamin-1 (EC 3.6.5.5) Dnm1
Dnm
16.874 0.000133 3.8771 0.00633 27.24975 27.13156 27.22933 26.941998





15.49 0.000199 3.7014 0.00868 24.70239 24.31222 24.70526 24.134963
P61161 Actin-related protein 2
(Actin-like protein 2)
Actr2 Arp2 15.215 0.000216 3.665 0.00893 24.06893 23.887608 24.00868 23.72985
P15105 Glutamine synthetase (GS) Glul Glns 14.75 0.00025 3.6022 0.00969 26.8151 26.797415 26.51625 26.618135
The numbers in the abundance column are the abundances normalized and averaged for four animals (two technical replicates/animal) in each group, and represented on a
log scale. All four groups were compared using one-way ANOVA and Fisher’s post-hoc test. The proteins that were significantly altered by p < 0.01 and FDR < 0.01, and
relevant to epileptogenesis/epilepsy are only listed in the table. Box plots for these proteins are included in Supplementary Figure 1. All other proteins are included in the
(Supplementary Table 1).
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TABLE 3 | The impact of intracerebral electrode implants on altered protein expression in the hippocampus.




log2(FC) P-value neg log10(p)
P98086 Complement C1q subcomponent subunit A C1qa 12,259 4.7473 2.2471 0.000337 3.4723
Q02105 Complement C1q subcomponent subunit C C1qc C1qg 12,262 4.2034 2.0715 0.000383 3.4169
P14106 Complement C1q subcomponent subunit B C1qb 12,260 3.4434 1.7838 0.000235 3.6293
P20152 Vimentin Vim 22,352 2.8094 1.4903 0.00067 3.174
P03995 Glial fibrillary acidic protein (GFAP) Gfap 14,580 2.7743 1.4721 3.33E-06 5.4779
Q8CIG9 F-box and leucine-rich repeat protein 8 Fbxl8 Fbl8 50,788 2.3142 1.2105 0.000804 3.095
P55012 Solute carrier family 12 member 2
(Basolateral Na-K-Cl symporter)
Slc12a2 Nkcc1 20,496 2.1188 1.0833 6.57E-05 4.1824
Q99L04 Dehydrogenase/reductase SDR family
member 1
Dhrs1 D14ertd484e 52,585 2.0032 1.0023 0.000742 3.1294
The groups compared were between the surgery vs. no surgery treated with vehicle (distilled water). The proteins that were significantly altered by p < 0.01 and >2-fold are only listed
in the table. All other proteins are included in Supplementary Table 2.
to have the lowest cytokine concentrations and one from an
electrode implanted and KA-treated mouse (surgery + KA) that
was anticipated to have the highest cytokine concentrations.
Based on the linearity of dilution results, 1:2 was considered to
be the optimum dilution for the quantification of inflammatory
cytokines using the MSD kit. We also determined whether the
cytokine levels in a 1:2 dilution of cortical supernatants lie within
the detectable (dynamic) range of the MSD assay. Six out of 10
cytokines showed concentrations within the anticipated dynamic
range for both samples (Table 5), suggesting the reliability of the
assay kit.
Cytokine Levels in Cortical Samples
We used cortical tissue to perform the cytokine assay. Surgical
implantation of intracerebral electrodes caused a significant
increase in the concentrations of proinflammatory cytokines
IFN-γ, IL-1β, IL-5, IL-6, IL-12p70, and TNFα irrespective of
the vehicle or KA treatment post-surgery (Figure 5). Likewise,
interestingly, the pleiotropic anti-inflammatory cytokines IL-4
and IL-10 were also increased in the mice that had intracerebral
electrodes irrespective of the vehicle or KA treatment post-
surgery (Figures 5I,J). KC/GRO was the only proinflammatory
cytokine that was increased in KA-treated group (naïve animals
without surgery). KC/GRO, however, was also upregulated
in surgery group treated with the vehicle but not with KA
(Figure 5G). In summary, surgery caused a significant increase in
all cytokine levels tested, except IL-2, irrespective of the vehicle or
KA treatment post-surgery.
Plasma Cytokine Levels
The effect of surgery and KA-induced seizures on the cytokine
profile was also investigated in plasma samples. Surgical
implantation of intracerebral electrodes caused a significant
increase in the plasma concentrations of proinflammatory
cytokines IL-1β, IL-5, IL-6, KC/GRO, and TNFα in the vehicle-
treated group (Figure 6). KA treatment, post-surgery, had no
effect on any of the plasma cytokines tested. However, KA in
naive animals (without surgery) increased IL-2 and KC/GRO
plasma levels (Figures 6C,G). The pleiotropic anti-inflammatory
cytokine IL-10 was increased in the mice that had intracerebral
electrodes and treated with the vehicle, but not KA, post-surgery
(Figure 6J). There were no significant effects of either surgery or
KA on plasma IFN-γ, IL-12p70, and IL-4 levels (Figures 6A,F,I).
It is unknown why there was increased plasma IL-1β in
the vehicle surgery group but not in the KA group (Fig. 6B).
However, in both KA groups, compared with the vehicle (no
surgery), there was an increase in IL-1β but the differences
were not statistically significant. The levels of IL-6 increased in
both surgery groups (with or without KA) in the hippocampus
(Figure 5E). In the plasma, we did observe increase of IL-6
in surgery group without KA, and an increase in KA without
surgery, but the differences in the latter were not significant
(Figure 6E). However, it is also unclear why there was no increase
of IL-6 and KC/GRO levels in KA+surgery group, though either
KA or surgery on their own caused an increase.
A summary of proteins that are relevant to
epileptogenesis/epilepsy/trauma, detected by proteomics
and cytokines/chemokines by multiplex assay, and the references
are tabulated in Table 6.
DISCUSSION
Intracranial Surgical Procedure Can
Compromise Seizure Threshold for
Chemoconvulsants
In this study, we observed a significant difference in KA
sensitivity for inducing generalized convulsive seizures in
animals that had intracerebral electrodes and without electrodes,
suggesting that surgical procedure and intracerebral electrodes
can impact seizure threshold in experimental models. This
finding is consistent with our previous observation in both
rat and mouse telemetry models in which the electrodes were
placed epidurally (2, 15, 25, 26). Both hippocampal proteomics
and cortical MSD cytokine analyses indicate that cellular
processes involved in neuroinflammation (including gliosis
and proinflammatory cytokines release), neurodegeneration,
synaptic plasticity, and reduced blood–brain barrier integrity
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FIGURE 3 | Fold change (FC) analysis of the vehicle or KA treated groups, with or without surgery, with a threshold of 2 was performed to compare the absolute
change between group values. The Volcano plots (A,C) were created to show both the fold change and the two-sample t-test analysis. The PCA analysis was
performed using the prccomp package, and pairwise score plots (B,D) and all four-way plot (E) represent an overview of the various separation patterns among the
most significant components.
were significantly altered as a consequence of the surgery and
implanted intracerebral electrodes.
Several studies have reported results from RNA microarrays
from both experimental models of epilepsy and human samples,
highlighting the role of certain genes in the development
of epilepsy (78–84). Sampling transcription, however, cannot
account for the numerous levels of post-transcriptional control,
which continue to emerge (85). Proteomics studies, therefore,
may offer a better insight into the molecular mechanisms of
the development of epilepsy. The first proteomics study was
from a C57BL/6J mouse model of epileptogenesis induced by
intrahippocampal KA injection (27). They compared the proteins
at 1, 3, and 30 days post-SE (27). Although their model involves
intracranial surgery for KA injection, and the same strain of
mouse as ours, intracerebral electrodes were not implanted
in their study. Furthermore, intrahippocampal KA does not
necessarily affect the cortex at an early stage of epileptogenesis,
as in the intraperitoneal KA approach (25, 26, 86–88). Our
recent proteomics on interventional studies in epileptogenesis
in the C57BL/6J mouse model, too, did not use intracerebral
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FIGURE 4 | Heatmaps—an overview of the variation in proteins between surgery and no surgery groups treated with either vehicle (A) or KA (B). NS, no surgery; S,
surgery.
TABLE 4 | The impact of KA-induced SE in intracerebral electrode implanted animals on the expression of proteins in the hippocampus.




log2(FC) P-value neg log10(p)
E9PV24 Fibrinogen alpha chain Fga 14,161 5.9018 2.5612 0.005928 2.2271
Q61838 Pregnancy zone protein (Alpha-2-macroglobulin) Pzp A2m 3.7671 1.9135 0.009382 2.0277
P07724 Serum albumin Alb Alb-1 Alb1 11,657 3.6877 1.8827 0.001262 2.899
Q921I1 Serotransferrin (Transferrin) (Beta-1 metal-binding
globulin)
Tf Trf 22,041 3.3186 1.7306 0.000404 3.3938
Q00897 Alpha-1-antitrypsin 1-4 (α-1 protease inhibitor 4) Serpina1d
Dom4 Spi1-4
20,703 2.5277 1.3378 0.008136 2.0896
Q8CIG9 F-box/LRR-repeat protein 8 Fbxl8 Fbl8 50,788 2.521 1.334 0.000421 3.3757
P14106 Complement C1q subcomponent subunit B C1qb 12,260 2.3267 1.2183 0.007832 2.1061




20,496 2.2689 1.182 0.001829 2.7379




2.0361 1.0258 0.000415 3.3817
Q8BTM8 Filamin-A (FLN-A) (Actin-binding protein 280) Flna Fln Fln1 192,176 2.0359 1.0257 0.006744 2.1711
The groups compared were between surgery vs. no surgery treated with KA. The proteins that were significantly altered by p < 0.01 and >2-fold are only listed in the table. All other
proteins are included in Supplementary Table 3.
electrodes (33). Another study on proteomics used an electric
kindling in the amygdala of female rats to induce epilepsy (29).
It is important to note that in this study, the electrodes
penetrated the cerebral hemispheres (Figure 1), and the KA was
administered as repeated low doses at 30min intervals via the
intraperitoneal route, 7 days after surgery, and the proteins were
analyzed a further 7 days later.
The Hippocampal Proteins That Mediate
Neurodegeneration
Comparing across all four groups, using one-way ANOVA
and Fisher’s post-hoc test, we found a significant increase
in some of the common proteins that have a role in
neuroinflammation and neurodegeneration, the two important
hallmarks of epileptogenesis associated with brain trauma or
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TABLE 5 | The linearity of dilution assessment and detection ranges of cytokines















IFN-γ 0.0471–815 321 346
IL-10 0.742–2,540 1,016 1,590
IL-12p70 7.98–22,900 429 422
IL-1 0.123–1,470 617 2,367
IL-2 0.259–2,110 441 581
IL-4 0.120–1,320 753 886
IL-5 0.0667–821 123 131
IL-6 0.830–3,490 846 3,838
KC/GRO 0.208–1,540 3,032 18,048
TNFα 0.127–507 866 1,124
Two cortical supernatants were used: one from a non-implanted, non-KA mouse (no
surgery + vehicle) that was expected to have the lowest cytokine concentrations and one
from an electrode implanted and KA-treated mouse (surgery + KA) that was predicted to
have the highest cytokine concentrations.
exposure to chemoconvulsants (2, 3, 15, 25, 26, 89, 90). Galectin-
1 (Gal-1) was significantly increased in response to surgery
with or without KA, but surgery seems to potentiate the KA
effects on Gal-1 expression (Supplementary Figure 1). It binds
to β-galactoside moieties present in cell surface glycoproteins
of neurons and astrocytes in the brain (91, 92). It is a member
of lectin family and a downstream effector of low affinity
nerve growth factor receptor, p75NTR, and regulates apoptosis
and axonal growth (93). A selective proapoptotic role of Gal-
1 in a subpopulation of GABAergic interneurons has been
demonstrated in a pilocarpine model of epilepsy (56). Gal-1
inhibits CD45 protein phosphatase and dephosphorylates Lyn
kinase, a member of the Src tyrosine kinase family (94, 95).
Interestingly, we also observed a significant reduction of another
member of Src kinase, Abl interactor 1 (Abi-1), in surgery group
with or without KA (Table 3). Abi-1 interacts with CaMKIIα and
regulates dendritic growth and spine maturation (96, 97). CD45,
a common leukocyte antigen, expression increases in epileptic
brain due to leaky BBB and infiltrated leukocytes (98). We also
demonstrated a significant increase in phosphorylated Src kinases
in a mouse model of epileptogenesis (2), suggesting a role for
galectin–CD45–Src kinase signaling pathway in epilepsy. Ras and
Rab related proteins, and CaMKIIα control neuronal plasticity
by coordinating dendritic filopodial motility and AMPA receptor
turnover (96, 97). In our proteomics study, Ras-related proteins
Rab-6A and R-Ras2, and CaMKIIα were significantly decreased
in surgery groups with or without KA, and with KA on its own
(without surgery) (Table 2, Supplementary Figure 1), implying
that the aberrant neurite growth and excitatory receptor activity
could exacerbate during epileptogenesis.
Cystatin-C (CysC) is an endogenous inhibitor of cysteine
protease such as cathepsin B (CatB) (99, 100). Interestingly, we
observed a significant increase of both CysC and CatB in surgery
groups with or without KA, but KA on its own did not increase
CatB (Table 2, Supplementary Figure 1). CysC modulates both
neurodegeneration and neurogenesis, during epileptogenesis and
in the established epilepsy (4). The increased expression of
CysC was observed in glial cells in the molecular layer of the
dentate gyrus and associated with granule cell dispersion in both
rat model and human patients with TLE (4). High levels of
CatB were reported in serum of human patients with surgically
resected temporal lobes (59) and in glial cells of progressive
myoclonic epilepsies (57), suggesting that CatB can be a potential
therapeutic target for certain epilepsies (58).
The Hippocampal Proteins Involved in BBB
Integrity
KA-induced SE in intracerebral electrodes mice significantly
increased the number of proteins related to BBB integrity. BBB
dysfunction occurs within hours of the insult in traumatic brain
injury patients and persists for days to weeks (101–104). Leaky
BBB has also been reported as a frequent event in post-traumatic
patients with epilepsy (105–107). BBB integrity is compromised
in response to KA-induced SE in experimental models (25, 26,
108). The fibrinogen alpha chain (FAC), a plasma glycoprotein,
was increased by 5.9-fold (p = 0.005) in the hippocampus in
the surgery+KA group when compared with no surgery+KA
group (Table 4). FAC protein infiltrates into the brain through
a leaky BBB and promotes neuroinflammation (60, 61). FAC
aids as an adhesive substrate for platelets, endothelial cells, and
leukocytes including brain infiltrated monocytes and further
increases vascular permeability by activating the extracellular
signal-regulated kinase 1/2 (ERK1/2) pathways in traumatic
brain injury (61, 90, 109). The significant increase of the
other serum glycoproteins in the hippocampus, such as serum
albumin, α2 macroglobulin, serotransferrin, and α1 protease
inhibitor 4 (α1 antitrypsin), further confirms the compromised
BBB integrity due to the brain trauma caused by intracerebral
electrodes and subsequent exposure to KA. The brain infiltrated
serum albumin binds to astrocytic transforming growth factor-
beta (TGF-β) receptors, phosphorylates SMAD-2/3, increases the
cytoskeletal proteins, and induces inflammatory signaling, thus
causing reactive gliosis (25, 26, 110–115). Indeed, we observed a
significant increase in three key cytoskeletal proteins: GFAP (2.7-
fold, p = 0.0003), vimentin (2.8-fold, p = 0.0007), and filamin
A (actin-binding protein 280, >2-fold, p = 0.006) in surgery
groups. Immunohistochemistry of mice brain sections from the
7 day post-KA of electrode implanted animals confirmed the
increased reactive astrogliosis (25, 26). In a model of acquired
epilepsy with BBB dysfunction, serum albumin has been shown
to induce excitatory synaptogenesis through astrocytic TGF-
β/ALK5 signaling pathway (116). There are reports of filamin
A pathology, as astrocytic inclusions, in human patients with
epilepsy (43, 44).
Glia-Related Proteins and Synaptic
Plasticity in the Hippocampus
We observed a significant increase in heat shock protein 25
(HSPβ1 or HSP25) in KA treated animals with or without
surgery (Table 2). HSP25 functions as a molecular chaperone
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FIGURE 5 | The effects of the vehicle or KA treatment in mice that had surgery for implantation of intracerebral electrodes or without surgery on inflammatory
cytokines in the cerebral cortex. The following cytokines were measured and represented in the graphs: (A) interferon-γ (IFN-γ), (B) interleukin-1β (IL-1β), (C)
interleukin-2 (IL-2), (D) interleukin-5 (IL-5), (E) interleukin-6 (IL-6), (F) interleukin-12p70 (IL-12p70), (G) keratinocyte-derived cytokine/growth-related oncogene
(KC-GRO), (H) tumor necrosis factor-α (TNF-α), (I) interleukin-4 (IL-4), (J) interleukin-10 (IL-10). The data are expressed as the mean (± SEM) cytokine concentration
in pg/mg protein. The values were compared across all four groups using one-way ANOVA with Tukey’s post-hoc test (n = 4, *p < 0.05; **p < 0.01; ***p < 0.001).
and regulates phosphorylation and the axonal transport of
neurofilament proteins (117). HSP25 was upregulated in
astrocytes and persisted for a long term in the hippocampus
after the induction of SE in a rat pilocarpine model (45).
The glutamine synthase (GS) and voltage-dependent GABA-
A transporter (GAT-1, encoded by SLC6A1) proteins were
significantly decreased in KA groups with or without surgery
(both, FDR < 0.01). GS was predominantly expressed in
astrocytes and required for the synthesis of glutamate and
ammonia in the brain. GS deficiency causes epilepsy in both
humans and animal models (46, 47). In a recent study, a
selective deletion of GS in the mouse cerebral cortex induced glial
dysfunction and vascular impairment (leaky BBB) that preceded
the onset of epilepsy and neurodegeneration (118). Gat-1 is one
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FIGURE 6 | The effects of the vehicle or KA treatment in the mice that had surgical implantation of EEG electrodes or without surgery on inflammatory cytokines in the
plasma from the same animals that were used for proteomics (hippocampi) and multiplex assay (cerebral cortices). The following inflammatory cytokines were
measured and represented in the graphs: (A) interferon-γ (IFN-γ), (B) interleukin-1β (IL-1β), (C) interleukin-2 (IL-2), (D) interleukin-5 (IL-5), (E) interleukin-6 (IL-6), (F)
interleukin-12p70 (IL-12p70), (G) keratinocyte-derived cytokine/growth-related oncogene (KC-GRO), (H) tumor necrosis factor-α (TNF-α), (I) interleukin-4 (IL-4), (J)
interleukin-10 (IL-10). The data are expressed as the mean (± SEM) cytokine concentration in pg/ml of plasma. The values were compared statistically using one-way
ANOVA with Tukey’s post-hoc test (n = 4, *p < 0.05; **p < 0.01; ***p < 0.001).
of the major GABA transporters in the brain and is responsible
for re-uptake of GABA by astrocytes at the synapses. The studies
in human patients revealed GAT-1 mutation/polymorphism in
febrile seizures, myoclonic-atonic seizures, and TLE (48, 49).
The activation of astrocytes and the induction of excitatory
synaptogenesis exacerbates the hyperexcitability of neurons,
which we had previously shown this phenomenon as an
increased epileptiform spiking during the first week of
epileptogenesis (2, 25, 26, 31). Activated astrocytes compromise
extracellular buffering at synapses by downregulating
Kir1.4 ion channels (25, 26). In this study, we also found
a significant change in the synaptic vesicle cycle and
glutathione metabolism pathways (Supplementary Table 5).
We have recently shown that activated astrocytes after
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TABLE 6 | Summary of altered hippocampal proteins and cortical and plasma proinflammatory cytokines and chemokines between groups.
Protein/cytokine/chemokine No surgery Surgery References related to epilepsy/seizure/trauma
Vehicle KA Vehicle KA
Gliosis related proteins
GFAP ++ ++++ +++ +++++ (25, 26, 39, 40)
Vimentin ++ ++++ +++ +++++ (41, 42)
Filamin A ++ ++ +++ +++ (43, 44)
Heat shock protein beta-1 (HSP 25) ++ ++++ ++ +++++ (45)
Glutamine synthase ++++ ++ +++ ++ (46, 47)
GAT-1 ++++ ++ +++ ++ (48, 49)
Complement C1qa + +++ ++++ ++++ (50–55)
Complement C1qb ++ +++ ++++ ++++
Complement C1qc ++ +++ ++++ ++++
Neurodegeneration related proteins
Galectin-1 ++ +++ +++ +++++ (56)
Cystatin-C (Cystatin-3) ++ +++ ++ +++ (4)
Cathepsin B ++ +++ ++ ++++ (57–59)
BBB integrity related proteins
Fibrinogen alpha chain ++ ++++ + +++ (60, 61)
Alpha 2 macroglobulin ++ +++ ++++ ++++ (62)
Transferrin ++ +++ ++++ ++++ (63)
α1 antitrypsin ++ ++ +++ ++++ (64)



























































































Relative abundance in each group is indicated by a plus sign.
SE induction produce complement C and chemokines,
which attract microglia at the synaptic terminals/neurons
(3, 23). In this study, we found a significant increase in
C1q related proteins in the surgery group with or without
KA exposure, suggesting the role of these proteins in
neuroinflammation and epileptogenesis. Several studies
have demonstrated both astrogliosis and microgliosis during
epileptogenesis and epilepsy (2, 3, 39, 40). A significant
increase in GFAP, vimentin, filamin A, and C1q proteins
in this study confirms that the proteomics method and the
analysis are reliable and reiterate the plausible role of the
identified proteins in the process of onset of spontaneous
recurrent seizures/epileptogenesis.
The Cortical and Peripheral Cytokines in
Response to Surgery and/or KA
Reactive astrocytes and microglia produce proinflammatory
cytokines (39, 40). The cytokine assay of the cerebral cortex
and the plasma from the same animals in our study showed
a significant increase in some of the key proinflammatory
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cytokines in the surgery group with or without KA when
compared with the group without surgery (Figures 5, 6).
Proinflammatory cytokines are well-known to lower the seizure
threshold (39, 40). Both hippocampus and cortex were affected
in both human and animal models of temporal lobe epilepsy
(25, 26, 86, 119–121). The epileptogenic network that involves
the initiation and propagation of seizures has been well-defined
in both humans and experimental models of epilepsy (115,
122, 123). Our previous work in the C57BL/6J mouse KA
model, focused on the hippocampus, the entorhinal cortex,
and the amygdala, suggested that the hippocampal gliosis and
neurodegenerative changes were maximally affected at 7 days
post-KA but beginning to decrease thereafter in contrast to the
rat KA model of progressive epilepsy (25, 26). Interestingly,
cortical changes persisted. Continuous video-EEG monitoring
from these mice revealed persistent non-convulsive seizures
(26). Therefore, in this study, we used the hippocampus for
protein profiling and the cerebral cortex, where the electrodes
penetrated the brain, for cytokine assay at 7 days post-KA (and
plasma from the same animals). It has been demonstrated that
the localized electrode-induced trauma causes localized gliosis
(124–126). We were also interested in determining whether
the impact of surgery and KA-induced SE or KA, on its own,
would change cytokine profiles in the plasma, which may serve
as a biomarker for epileptogenesis in experimental models.
Indeed, we observed a significant increase in pro-inflammatory
cytokines IFN-γ, IL-1β, IL-5, 1L-6, IL-10, IL-12p70, KC/GRO
(also known as CXCL1), and TNFα in the cerebral cortex in
the surgery group, and some in KA, suggesting the occurrence
of neuroinflammation due to implanted electrodes and/or KA.
Appropriate references with respect to the roles of these cytokines
in epilepsy/seizure/trauma are included in Table 6. In the plasma
of KA-induced SE in animals without surgery, only IL-2 and
KC/GRO were upregulated. Interestingly, IL-2 was unaffected
in the cerebral cortex, implying the peripheral effects. Although
there is no literature on either plasma/serum or cerebral tissue
cytokines at 14 days post-trauma, there are reports on early time-
points demonstrating upregulation of some of these cytokines
(89, 127). Therefore, the plausible reason for the reduced seizure
threshold in the mice that had surgery could be due to localized
cerebral inflammation, which seems to have persisted for a
further 7 days as a result of the implanted electrodes.
The occurrence of seizures immediately prior to euthanasia
could affect some of the cytokine levels. In this study, we
did not monitor the animals for seizures throughout. Once a
spontaneous seizure was confirmed in amouse, the recording was
stopped. An important variable in this study and Ravizza et al.
(128) is the model (pilocarpine rat model vs. KA mouse model).
The rat pilocarpine model is a progressive epilepsy model, while
C57BL/6J mouse KA model is a regressive model (convulsive
seizures are infrequent) (129).
The Limitations of This Study
The proteins discussed in this study, focused on the effects of
surgery and KA on the development of epilepsy, are based on
the literature. We have investigated the hippocampus only for
proteomes and the cortex only for cytokines at 7 day post-KA
(only one time-point), and the other epileptogenic areas and
the time-points were not investigated. It has been suggested
that the endogenous proresolving molecules such as lipoxins,
resolvins, protectins, and maresins synthesis occur within hours
to days of insult (130). In this study, none of the proresolving
endogenous mediators of inflammation were significantly altered
in any groups. Since we did proteomics at 14 days post-surgery or
7 days post-SE, it is likely that the resolution phase has passed. For
example, the brain infiltrated monocytes and leucocytes persist
only during the first 3 days of chemoconvulsant-induced SE
(131). The altered levels of proteins or cytokines/chemokines
alone do not necessarily affect the brain function per se. In
this context, further studies are needed to determine the cell
types and the receptor subtype expression in different regions
of the brain at various time points post-SE to determine the
functional outcome.
A summary of proteins identified in this study with a
known role in seizures/epilepsy/trauma are listed in Table 6.
In addition to the proteins discussed, there are many other
proteins that may have a role in epileptogenesis that were
not detected in this study due to single time point analysis.
However, a few other proteins that were altered due to
surgery and/or KA are briefly mentioned here. VGF, a BDNF-
inducible peptide precursor, regulates fear-associated memory
formation in hippocampus (132–134). Glypican-1, a member of
the heparin sulfate proteoglycans, mediates phosphatidylinositol
glycan signal propagation and receptor activation in the brain.
Although glypican-4 has been demonstrated in the brains
of epileptic patients and epileptic animals (135), the role of
glypican-1 in epileptogenesis is yet unknown. Unconventional
myosin-Va is required for neuronal plasticity, motor learning,
oligodendrocyte morphogenesis, and myelination (136, 137),
but its role in epileptogenesis is also unknown. Further
mining of the proteomics data can yield other molecular
mechanisms that may be affected by surgery and KA. The
raw data and analyzed data are available at https://github.com/
ISUgenomics/2020_Thippeswamy_Surgery-Proteomics/tree/ or
via ProteomeXchange (Project doi: 10.6019/PXD021554). The
results of this study did not show significant changes in the
other proteins of certain pathways such as glutamate receptor
activation, immunomodulating effects, or calcium homeostasis;
however, the identified proteins having a significant role in
inflammation, neurodegeneration, BBB integrity, and gliosis
support the hypotheses of the potential impact of intracerebral
electrodes on brain pathology and electrical activity. Surgery and
intracerebral electrodes can alter chemoconvulsants’ sensitivity
in animals and appear to have a higher impact on altering
the expression of proteins involved in epilepsy than KA itself.
Thus, it can be misleading to assume that the development
of epilepsy observed in EEG will reflect what occurs in brains
without electrodes. These findings should give insights into the
impact of intracranial surgery on epilepsy development and
should be considered in the design of epilepsy studies and the
interpretation of data arising from models in which intracranial
procedures have been used. It should be noted that the sample
size used in this study is small (n = 4) as in the rat pilocarpine
model (28). However, a combination of proteomics andmultiplex
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assay from two different brain regions, and the plasma assay,
revealed the altered key proteins in trauma and/or KA-induced
brain injury.
In conclusion, surgery and intracerebral electrodes reduce
seizure threshold and increase the key proteins that regulate
the BBB function, neuroinflammation, and neurodegeneration as
revealed by the proteomics at 7 days post-KA. The cytokine assay
from the cerebral cortex and plasma suggest that the intracerebral
electrode-induced proinflammatory cytokine responses may
partly contribute to the decreased seizure threshold but not
necessarily promote epileptogenesis, which was not tested in this
study. It should also be noted that some of the inflammatory
molecules (IL-6, IL-1beta, KC/GRO) reported in this study are
inconsistent and require further investigation. The transient
inflammatory responses evoked by surgery and electrodes
procedures (persistent responses at different time-points were
not tested in this study) unlikely have an impact on the
development of epilepsy; otherwise, it is difficult to extrapolate
the refined experimental models of SE induction by electrical
stimulation in which only a small percentage of animals develop
epilepsy (138). Our past EEG studies in the C57BL/6J mice did
not show epileptiform spikes in their baseline EEG during the
first 10 days of continuous (24/7) EEG monitoring post-surgery
before KA challenge, suggesting that mere electrode implantation
per se unlikely initiates epileptogenesis (129). However, the
surgical procedure decreases the seizure threshold; therefore, to
reduce mortality in KA models, irrespective of rodent species,
a repeated low-dose method of administering KA would be
advantageous (32, 139).
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